ArticlePharmaceuticals (Basel, Switzerland)2023
The Parasite Reduction Ratio (PRR) Assay Version 2: Standardized Assessment of
Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Using Next Generation Chemiluminescent Probes to Improve theACS infectious diseases · 2026Article
- Clinically applicable parasite viability assay for rapid assessment of antimalarial pharmacodynamic endpoints.Antimicrobial agents and chemotherapy · 2025Article
- Structure-Based Discovery and Development of Highly Potent Dihydroorotate Dehydrogenase Inhibitors for Malaria Chemoprevention.Journal of medicinal chemistry · 2025Article
- Accelerating Antimalarial Drug Discovery with a New High-Throughput Screen for Fast-Killing Compounds.ACS infectious diseases · 2024Article
- An adaptable, fit-for-purpose screening approach with high-throughput capability to determine speed of action and stage specificity of anti-malarial compounds.Antimicrobial agents and chemotherapy · 2024Article
- Towards clinically relevant dose ratios for Cabamiquine and Pyronaridine combination using P. falciparum field isolate data.Nature communications · 2024Article
- Aryl amino acetamides prevent Plasmodium falciparum ring development via targeting the lipid-transfer protein PfSTART1.Nature communications · 2024Article
- Understanding the Antiplasmodial Action of Resistance-Refractory Xanthoquinodin A1.ACS infectious diseases · 2024Article
- Defining the next generation of severe malaria treatment: a target product profile.Malaria journal · 2024Review
- Differential effects of translation inhibitors onLife science alliance · 2024Article
- Next Generation Chemiluminescent Probes for Antimalarial Drug Discovery.ACS infectious diseases · 2024Article
- IncompleteFrontiers in cellular and infection microbiology · 2024Article
- Translation inhibition efficacy does not determine thebioRxiv : the preprint server for biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
Abstract
With artemisinin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.